FDA Inspection 754506 — Dhaliwal Labs South LLC

Dhaliwal Labs South LLC — FEI 3007410731

The FDA completed an inspection of Dhaliwal Labs South LLC on December 15, 2011 in Dallas, TX. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 20 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
December 15, 2011
Fiscal Year
2012
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Dallas, TX (United States)

Citations

IDCFRDescription
103321 CFR 211.22(a)Authority lacking to review records, investigate errors
117721 CFR 211.63Equipment Design, Size and Location
121521 CFR 211.67(b)Written procedures not established/followed
122721 CFR 211.67(c)Cleaning/maintenance records not kept
136121 CFR 211.100(a)Absence of Written Procedures
1471221 CFR 820.184DHR - not or inadequately maintained
154021 CFR 211.125(a)Strict control not exercised over labeling issued
178721 CFR 211.80(a)Procedures To Be in Writing
180121 CFR 211.84(a)Components withheld from use pending release
191221 CFR 211.166(a)Written program not followed
200321 CFR 211.184(c)Individual inventory record
200921 CFR 211.188Prepared for each batch, include complete information
232721 CFR 820.22Quality audits - Lack of or inadequate procedures
311721 CFR 820.70(i)Software validation for automated processes
356921 CFR 211.89Quarantine of Rejected Components et. al.
358221 CFR 211.105(a)Identification of containers, lines, equipment
360321 CFR 211.160(b)Scientifically sound laboratory controls
430721 CFR 211.80(d)Status of Each Lot Identified
437221 CFR 211.188(b)(8)Labeling control records including specimens or copies
439121 CFR 211.180(e)(2)Items to cover on annual reviews